Literature DB >> 2569599

Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome.

K D Forsyth1, A C Simpson, M M Fitzpatrick, T M Barratt, R J Levinsky.   

Abstract

Neutrophil leucocytosis is associated with a poor outcome in the haemolytic uraemic syndrome (HUS). This study tested the hypothesis that neutrophils from HUS patients are activated and through release of their intracellular contents damage endothelium. The proportion of neutrophils adhering to endothelium in culture was twice as high for HUS patients' neutrophils as for control neutrophils (n = 12). In addition, these neutrophils induced endothelial injury, assessed morphologically by degradation of endothelial cell fibronectin. In an attempt to inhibit neutrophil adhesion and subsequent endothelial damage the hyperadhesive neutrophils from HUS patients were incubated with a CD18 antibody directed against the common beta chain of the leucocyte integrin molecules. The CD18 antibody was able to abrogate endothelial damage in four of the ten subjects studied. These observations suggest that the neutrophil is of prime pathophysiological importance in HUS, and that methods aimed at reducing neutrophil adhesion and neutrophil-mediated endothelial damage are likely to be beneficial.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569599     DOI: 10.1016/s0140-6736(89)90591-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7.

Authors:  J Liu; T Akahoshi; T Sasahana; H Kitasato; R Namai; T Sasaki; M Inoue; H Kondo
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  New insights into the haemolytic uraemic syndromes.

Authors:  D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

3.  Anti-CD9 antibodies augment neutrophil adherence to endothelium.

Authors:  K D Forsyth
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 4.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response.

Authors:  Hiroaki Yamazaki; Nobuhiko Hiramatsu; Kunihiro Hayakawa; Yasuhiro Tagawa; Maro Okamura; Ryouji Ogata; Tao Huang; Shotaro Nakajima; Jian Yao; Adrienne W Paton; James C Paton; Masanori Kitamura
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

7.  Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury.

Authors:  Junichi Hirahashi; Keiichi Hishikawa; Shinya Kaname; Naotake Tsuboi; Yunmei Wang; Daniel I Simon; George Stavrakis; Tatsuo Shimosawa; Ling Xiao; Yutaka Nagahama; Kazuo Suzuki; Toshiro Fujita; Tanya N Mayadas
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

8.  Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

Authors:  I Pela; D Seracini; A Caprioli; F Castelletti; A Giammanco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

9.  Verotoxin activates mitogen-activated protein kinase in human peripheral blood monocytes: role in apoptosis and proinflammatory cytokine release.

Authors:  Pamela Cameron; Susan J Smith; Mark A Giembycz; Dino Rotondo; Robin Plevin
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

10.  Decreased plasma fibronectin concentrations in preterm infants with septicaemia.

Authors:  M P Dyke; K D Forsyth
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.